Evidence map›Paper›PMID 41957374›Full record

ArticleNature communications2026

Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification.

Chunling Hu, Sounak Sahu, Wenan Chen, Melissa Galloux, Marcy E Richardson, Megan F Bishop, Rachid Karam, Tina Pesaran, Jie Na, Huaizhi Huang and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Reclassification ofCurrent oncology (Toronto, Ont.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Chunling Hu *Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6814-4639
Sounak Sahu *Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0001-7290-6651
Wenan ChenDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-0379-2368
Melissa GallouxIndependent Bioinformatician, Marseille, France.ORCID 0009-0009-4424-6815
Marcy E RichardsonAmbry Genetics, Aliso Viejo, CA, USA.ORCID 0000-0002-4626-4920
Megan F BishopDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Rachid KaramAmbry Genetics, Aliso Viejo, CA, USA.ORCID 0000-0002-5645-498X
Tina PesaranAmbry Genetics, Aliso Viejo, CA, USA.ORCID 0000-0001-9807-4304
Jie NaDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Huaizhi HuangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0009-0001-6186-7228
Jeffrey N WeitzelDivision of Precision Prevention, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0001-6714-092X
Katherine N NathansonPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6740-0901
Siddhartha YadavDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4630-9903
Nicholas J BoddickerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Susan M DomchekPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-5914-7272
Alvaro N MonteiroDepartment of Epidemiology, H. Lee Moffitt Cancer Center,, Tampa, FL, USA.ORCID 0000-0002-8448-4801
Edwin S IversenDepartment of Statistical Science, Duke University, Raleigh Durham, NC, USA.ORCID 0000-0002-0066-2763
Shyam K SharanMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA. sharans@mail.nih.gov.ORCID 0000-0002-9333-870X
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. couch.fergus@mayo.edu.ORCID 0000-0001-9417-9985

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Resolving the cancer relevance of predisposition gene mutationsR35CA253187 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2020 to 2026
$5.8M
Curation Expert Panels for BRCA1/2 and Hereditary Breast, Ovarian and Pancreatic (HBOP) Cancer GenesU24CA258058 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2022 to 2026
$1.3M
Breast Cancer Research Foundation (BCRF) BCRF-24-030NCI NIH HHS P50 CA116201NCI NIH HHS R35 CA253187NCI NIH HHS U24 CA258058U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) Intramural Program
6 · The paper itself

Abstract

Determining the clinical relevance of BRCA2 variants of uncertain significance is critical for informed risk management. Recently, two saturation genome editing studies assessed the functional effects of all single nucleotide variants in the BRCA2 C-terminal DNA Binding Domain. To improve the accuracy of functional data used for ACMG/AMP variant classification, we combined results from these studies in four composite models and evaluated the performance of each model using variants with known classifications. Here, we show that an "Integrated VarCall Model", which combined raw functional data for 6383 variants from the original studies, yielded 98.8% accuracy and out-performed the original studies and other combined data models. Incorporation of the "Integrated VarCall Model" functional data with other sources of evidence according to ClinGen BRCA1/2 variant curation expert panel specifications resulted in classification of 5926 (92.8%) BRCA2 variants as pathogenic (n = 735) or benign (n = 5191) and provides valuable insights for individuals with BRCA2 variants.

Indexed as

BRCA2 ProteinGenetic VariationFemaleHumansPolymorphism, Single NucleotideBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID41957374
PMCPMC13223280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.